Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
暂无分享,去创建一个
A. Ascherio | D. Dluzen | M. Schwarzschild | Kui Xu | Yuehang Xu | Jiang-fan Chen | Deborah Brown-Jermyn
[1] T. L. Thompson,et al. Estrogen mediated inhibition of dopamine transport in the striatum: Regulation by Gαi/o , 2005 .
[2] E. Bastia,et al. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. , 2005, Pharmacology & therapeutics.
[3] M. Joghataie,et al. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. , 2004, Parkinsonism & related disorders.
[4] M. Thun,et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. , 2004, American journal of epidemiology.
[5] A. Mendelowitsch,et al. Acute effects of 17β-estradiol on the extracellular concentration of excitatory amino acids and energy metabolites during transient cerebral ischemia in male rats , 2004, Brain Research.
[6] T. Saleh,et al. Estrogen attenuates neuronal excitability in the insular cortex following middle cerebral artery occlusion , 2004, Brain Research.
[7] N. Pedersen,et al. No evidence for heritability of Parkinson disease in Swedish twins , 2004, Neurology.
[8] Roberta Diaz Brinton,et al. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease , 2004, Experimental Neurology.
[9] E. Bézard,et al. Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.
[10] F. Menniti,et al. Repeated Estradiol Treatment Prevents MPTP-Induced Dopamine Depletion in Male Mice , 2003, Neuroendocrinology.
[11] F. Speizer,et al. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease , 2003, Neurology.
[12] L. Griffiths,et al. The measurement of adenosine and estrogen receptor expression in rat brains following ovariectomy using quantitative PCR analysis. , 2003, Brain research. Brain research protocols.
[13] M. Schwarzschild,et al. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice , 2002, Neuroscience Letters.
[14] W. Willett,et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.
[15] M. Schwarzschild,et al. Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[16] D. Dluzen,et al. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system , 2001, Neuroscience.
[17] D. Schaid,et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2000, Neurology.
[18] G. Tucker,et al. Parkinson's disease and CYP1A2 activity. , 2000, British journal of clinical pharmacology.
[19] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[20] M. Folan,et al. Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women , 1999, Journal of clinical pharmacology.
[21] B. Fredholm,et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.
[22] J W Langston,et al. Parkinson disease in twins: an etiologic study. , 1999, JAMA.
[23] H. Yamazaki,et al. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.
[24] J. O'Callaghan,et al. The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.
[25] J. Cadet,et al. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent , 1996, Brain Research.
[26] D. Dluzen,et al. Estrogen Alters MPTP‐Induced Neurotoxicity in Female Mice: Effects on Striatal Dopamine Concentrations and Release , 1996, Journal of neurochemistry.
[27] R. Tukey,et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. , 1994, Biochemical pharmacology.
[28] T. Di Paolo,et al. Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. , 1993, Biochemical pharmacology.
[29] F. Gonzalez,et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.
[30] J. Langston,et al. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment , 1992, Brain Research.
[31] S. Schenker,et al. Impaired elimination of caffeine by oral contraceptive steroids. , 1980, The Journal of laboratory and clinical medicine.
[32] T. L. Thompson,et al. Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. , 2005, European journal of pharmacology.
[33] D. Abernethy,et al. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives , 2004, European Journal of Clinical Pharmacology.
[34] D. Inzitari,et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. , 2000, Neurology.
[35] W. J. Brooks,et al. Influence of sex, age and strain on MPTP-induced neurotoxicity , 1989 .
[36] T. Di Paolo,et al. Striatal D-2 dopamine agonist binding sites fluctuate during the rat estrous cycle. , 1988, Life sciences.